基于生物信息学的十二指肠腺瘤核心致病基因及其靶向治疗中药活性成分筛选

Abstract
Figure/Table
References (0)
Related Citation (8)

Download: PDF (6881 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To screen and analyze the core pathogenic genes of Duodenal Adenoma （DA） by using bioinformatics methods, and discover the active components of Chinese materia medica that may be used for targeted treatment of DA. Methods: DA data set GSE102208 was downloaded from GEO database, GEO2R was used to screen differentially expressed genes （DEGs）, DAVID database was used to perform GO and KEGG enrichment analysis of DEGs, STRING database was used for proteinprotein interaction（PPI）analysis, and Cytoscape was applied to obtain DA core pathogenic genes. The CTD database was used to obtain targeted Chinese medicine active components that act on core pathogenic genes. Results: A total of 373 differentially expressed genes between DA patients and normal people were screened, including 270 upregulated genes and 103 downregulated ones, which were mainly involved in cholesterol import, cholesterol homeostasis, cholesterol efflux, lipoprotein biosynthetic process, triglyceride homeostasis and other biological processes and enriched in signaling pathways including PI3kAKT, PPAR, carbohydrate digestion and absorption, protein digestion and absorption, fat digestion and absorption, and bile secretion. Ten key genes including ApoB, EGF, ApoA1, SLC2A2, MGAM were screened out. Further analysis revealed potential targeted Chinese medicine active components including Resveratrol, Quercetin, Ginsenoside, Curcumin, Tripterygium Wilfordii. Conclusion: Public databases may be used to screen the gene targets closely related to the occurrence and development of DA, and explore the active components of Chinese materia medica that may be used for DA targeted therapy.

Received: 22 October 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2021/V31/I02/158

［1］Matsuzaki J, Suzuki H, Shimoda M, et al. Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma\[J\]. United European Gastroenterol J, 2019, 7（2）: 250-260.

［2］Ochiai Y, Kato M, Kiguchi Y, et al. Current status and challenges of endoscopic treatments for duodenal tumors\[J\]. Digestion, 2019, 99（1）: 21-26.

［3］Thiruvengadam SS, O′Malley M, LaGuardia L, et al. Gene expression changes accompanying the duodenal adenomacarcinoma sequence in familial adenomatous polyposis\[J\]. Clin Transl Gastroenterol, 2019, 10（6）: e00053.

［4］Niwa A, Kuwano S, Tomita H, et al. The different pathogeneses of sporadic adenoma and adenocarcinoma in nonampullary lesions of the proximal and distal duodenum\[J\]. Oncotarget, 2017, 8（25）: 41078-41090.

［5］Kojima Y, Ohtsuka K, Ohnishi H, et al. APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas\[J\]. Surg Today, 2018, 48（8）: 765-772.

［6］Sakaguchi Y, Yamamichi N, Tomida S, et al. Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas\[J\]. J Gastroenterol, 2019, 54（2）: 131-140.

［7］Davis AP, Grondin CJ, Johnson RJ, et al. The comparative toxicogenomics database: update 2019\[J\]. Nucleic Acids Res, 2019, 47（D1）: D948-D954.

［8］Sharma B, Agnihotri N. Role of cholesterol homeostasis and its efflux pathways in cancer progression\[J\]. J Steroid Biochem Mol Biol, 2019, 191（1）: 105377.

［9］Goossens P, RodriguezVita J, Etzerodt A, et al. Membrane cholesterol efflux drives tumorassociated macrophage reprogramming and tumor progression\[J\]. Cell Metab, 2019, 29（6）: 1376-1389.

［10］Han S, Pan Y, Yang X, et al. Intestinal microorganisms involved in colorectal cancer complicated with dyslipidosis\[J\]. Cancer Biol Ther, 2019, 20（1）: 81-89.

［11］Ganjali S, Ricciuti B, Pirro M, et al. Highdensity lipoprotein components and functionality in cancer: stateoftheart\[J\]. Trends Endocrinol Metab, 2019, 30（1）: 12-24.

［12］Uko NE, Güner OF, Matesic DF, et al. Akt pathway inhibitors\[J\]. Curr Top Med Chem, 2020, 20（10）: 883-900.

［13］Wagner KD, Du S, Martin L, et al. Vascular PPARβ/δ promotes tumor angiogenesis and progression\[J\]. Cells, 2019, 8（12）: 1623.

［14］Ren L, Yi J, Li W, et al. Apolipoproteins and cancer\[J\]. Cancer Med, 2019, 8（16）: 7032-7043.

［15］Kim NH, Suh JY, Park JH, et al. Parameters of glucose and lipid metabolism affect the occurrence of colorectal adenomas detected by surveillance colonoscopies\[J\]. Yonsei Med J, 2017, 58（2）: 347-354.

［16］AlJawadi A, Patel CR, Shiarella RJ, et al. Celltypespecific, ketohexokinasedependent induction by fructose of lipogenic gene expression in mouse small intestine\[J\]. J Nutr, 2020, 150（7）: 1722-1730.

［17］Zhang T, Wang Q, Wang Y, et al. AIBP and APOAI synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux\[J\]. J Transl Med, 2019, 17: 161.

［18］Nagano H, Tomida C, Yamagishi N, et al. VEGFR1 regulates EGFR to promote proliferation in colon cancer cells\[J\]. Int J Mol Sci, 2019, 20（22）: 5608.

［19］Loh CY, Chai JY, Tang TF, et al. The Ecadherin and Ncadherin switch in epithelialtomesenchymal transition: signaling, therapeutic implications, and challenges\[J\]. Cells, 2019, 8（10）: 1118.

［20］Daulagala AC, Bridges MC, Kourtidis A. Ecadherin beyond structure: a signaling hub in colon homeostasis and disease\[J\]. Int J Mol Sci, 2019, 20（11）: 2756.

［21］Zhao Y, Yu T, Zhang N, et al. Nuclear Ecadherin acetylation promotes colorectal tumorigenesis via enhancing βcatenin activity\[J\]. Mol Cancer Res, 2019, 17（2）: 655-665.

［22］Tashiro E, Henmi S, Odake H, et al. Involvement of the MEK/ERK pathway in EGFinduced Ecadherin downregulation\[J\]. Biochem Biophys Res Commun, 2016, 477（4）: 801-806.

［23］Li ZY, Shi YL, Liang GX, et al. Visualization of GLUT1 trafficking in live cancer cells by the use of a dualfluorescence reporter\[J\]. ACS Omega, 2020, 5（26）: 15911-15921.

［24］Jeppsson S, Srinivasan S, Chandrasekharan B. Neuropeptide Y （NPY） promotes inflammationinduced tumorigenesis by enhancing epithelial cell proliferation\[J\]. Am J Physiol Gastrointest Liver Physiol, 2017, 312（2）: G103-G111.

［25］Guo T, Chen T, Gu C, et al. Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer\[J\]. Tumour Biol, 2015, 36（10）: 7649-7658.

［26］Han Y, Jo H, Cho JH, et al. Resveratrol as a tumorsuppressive nutraceutical modulating tumor microenvironment and malignant behaviors of cancer\[J\]. Int J Mol Sci, 2019, 20（4）: 925.

［27］Yuan L, Zhou M, Huang D, et al. Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial mesenchymal transition via the AKT/GSK3β/Snail signaling pathway\[J\]. Mol Med Rep, 2019, 20（3）: 2783-2795.

［28］ReyesFarias M, CarrascoPozo C. The anticancer effect of Quercetin: molecular implications in cancer metabolism\[J\]. Int J Mol Sci, 2019, 20（13）: 3177.

［29］Luo H, Vong CT, Chen H, et al. Naturally occurring anticancer compounds: shining from Chinese herbal medicine\[J\]. Chin Med, 2019, 14（1）: 48.

［30］Dai G, Sun B, Gong T, et al. Ginsenoside Rb2 inhibits epithelialmesenchymal transition of colorectal cancer cells by suppressing TGFβ/Smad signaling\[J\]. Phytomedicine, 2019, 56（1）: 126-135.

［31］Telang N. Stem cell models for genetically predisposed colon cancer\[J\]. Oncol Lett, 2020, 20（5）: 138.

［32］Noel P, Von Hoff DD, Saluja AK, et al. Triptolide and its derivatives as cancer therapies\[J\]. Trends Pharmacol Sci, 2019, 40（5）: 327-341.